EDGE-TO-EDGE REPAIR (TEER)
MitraClip™ is the first minimally invasive TEER* therapy that delivers a life-changing treatment option for selected patients with Primary Mitral Regurgitation (PMR) or Secondary Mitral Regurgitation (SMR) who would otherwise go untreated.1,2 MitraClip™ is the standard of care in TMVr built on proven mitral valve therapy with over 20 years of experience, an extensive body of clinical evidence, and more than 200,000 patients treated worldwide.3
MitraClip™ TEER is a minimally invasive treatment option for select patients with:
THE CATALYST FOR A SIGNIFICANT EVOLUTION
IN MR GUIDELINE
MitraClip™ is the first TMVr (TEER) therapy recommended by the American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines and the Asian Pacific Society of Cardiology (APSC) consensus recommendations for selected PMR and SMR* patients. The guidelines support aggressive monitoring and early action, with the goal of preventing complications due to Left Ventricular (LV) volume overload.4,10-12
GUIDELINES
KEY PATIENT INFORMATION
SEVERE MR IS VASTLY UNDERTREATED
Surgical intervention not offered or denied
49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.5
If left untreated, MR initiates a cascade of events leading to death, with 1-year mortality up to 57%.6
Hub
TV
AV VALVES 2023: Fast Forward 20 Years
AV VALVES 2023: The Genesis of TEER
AV VALVES 2023: TA, TF in TMVR
AV VALVES 2023: Replace, Repair in TR
AV VALVES 2023: Staged, Concomitant
AV VALVES 2023:Decision Making in HF–Tricuspid
AV VALVES 2023:Decision Making in HF – Mitral
AV VALVES 2023:HF and VHD – Patient Management
AV VALVES 2023: MR – Mixed MR
AV VALVES 2023: MR – Acute Rupture
*The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual’s experience and might not be representative of others.
**Tests performed by and data on file at Abbott.
- MitraClip™ G4 System Instructions for Use.
- Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after the transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64(2):182–192. doi.org/10.1016/j.jacc.2013.10.021.
- Data on file at Abbott.
- Heidenreich PA, Bozkurt B, Allen LA, et al. “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association. Joint Committee on Clinical Practice Guidelines.” J Am Coll Cardiol. 2022;28(5):E1–E167. doi.org/10.1016/j.cardfail.2022.02.010.
- Mirabel M, Lung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358–1365. doi.org/10.1093/eurheartj/ehm001.
- Cioffi G, Tarantini L, De Feo S, et al. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail. 2005;7(7):1112–1117. doi.org/10.1016/j.ejheart.2005.01.016.
- Rottbauer WD. Contemporary Clinical Outcomes with MitraClip™ (NTR/XTR) System: Core-lab Echo Results from +1000 Patient the Global EXPAND Study. Data presented at PCR 2020.
- Maisano F. Clip Selection Strategy and Outcomes with MitraClip™ (NTR/XTR): Evidence-Based Recommendations from the Global EXPAND Study. Data presented at PCR 2020.
- Rodriguez E. Contemporary Outcomes with the MitraClip™ G4 System: Preliminary Results based on the EXPAND G4 Study. Data presented at TCT 2021.
- Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group, 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J.2022;43(7):561–632, doi.org/10.1093/eurheartj/ehab395.
- Yeo KK, Tan JWC, Muller DW, et al. Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation. Eur Cardiol. 2021;16:e25. doi.org/10.15420/ecr.2021.01.
- McDonagh TA, Metra M, Adamo M, et al., ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J.2012; 42(36):3599–3726, doi.org/10.1093/eurheartj/ehab368.